FORMULATION AND DEVELOPMENT OF LAMIVUDINE ANTI HIV MATRIX TABLETS

In Present Research Work To Develop Lamivudine Extended Tablets For Prolong Release and Increased Gastric Retention Time. Lamivudine Is the Approved Compound For The treatment of AIDS; However the Main Limitation to Therapeutic Effectiveness of Lamivudine Is Its Dose dependent Toxicity, Short Biological Half-Life and High Bioavailability. Fourier Transform Infrared Spectroscopy That No Interactions between drug, polymer and excipients. Tablets Were Prepared By Direct Compression Method Using Different Polymers Eudragit S 100 And Eudragitl-100 are different excipients and different concentration of polymers containing F1-F9 Formulation In Different Ratio Of Polymers and different evaluation parameter Hardness thickness, weight variation friability and optimised formulation F6 And Drug Release Is 99.37% , Its Is Due To Increase Polymer Concentration and Release of drug follows first Order and It was shown non fickians (case-II) (anomalous) transport diffusion mechanism.